Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, single-sequence pharmacokinetic study in healthy subjects to assess the potential of AEB071 to inhibit and induce CYP1A2 using caffeine as a probe substrate.

Next Previous
Trial Profile

An open-label, single-sequence pharmacokinetic study in healthy subjects to assess the potential of AEB071 to inhibit and induce CYP1A2 using caffeine as a probe substrate.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotrastaurin (Primary) ; Caffeine
  • Indications Liver transplant rejection; Psoriasis; Renal transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Novartis

Most Recent Events

  • 07 Jan 2013 Status changed from recruiting to active, no longer recruiting, according to Clinical Trials Registry - India
  • 10 Feb 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top